We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Elvira
Bramon
e.bramon@ucl.ac.uk
Rosemary
Abidoph
rosemary.abidoph@nhs.net
Oriella
Stellakis
uctvocs@ucl.ac.uk
Lauren
Varney
uctvlva@ucl.ac.uk
Maria
Richards-Brown
mrichards.brown@gmail.com
Lauren
Varney
lauren.varney.21@ucl.ac.uk
Prof
Elvira
Bramon
e.bramon@ucl.ac.uk
Prof
Elvira
Bramon
e.bramon@ucl.ac.uk
Emmanuel
Rollings-Kamara
emmanuel.rollings-kamara@nihr.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Mood [affective] disordersSchizophrenia, schizotypal and delusional disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Schizophrenia and bipolar disorder constitute one of the leading causes of disability in young adults. Depression is a highly common condition affecting about one in four people. Antipsychotics and antidepressants are the most common treatment for these illnesses. Although they are effective for many patients they can also cause severe side effects. As a result of this patient adherence is low.
It is possible that genetic differences could explain why some patients respond to their treatment better than others and also why some patients experience severe side effects. By running this study, we seek to investigate if genetic profiling can help optimise the prescribing of psychotropic medications and lead to improved clinical outcomes and reduced side effects.
Participants who consent to take part in the study will be offered genome-wide genotyping. We will recruit adult patients with schizophrenia, delusional, schizoaffective or bipolar disorders. The initial assessment will take place on the hospital ward or at a community centre if the participant is an outpatient. The follow-up assessment can take place on the ward or in the community if the patient has been discharged. The final follow-up will be undertaken based on clinical records.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Drug;
You can take part if:
You may not be able to take part if:
The principal exclusion criteria is as follows: (1) Patients with current high risk of self-harm or harm to others. (2) Patients who lack capacity to consent to taking part in the research.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Elvira
Bramon
e.bramon@ucl.ac.uk
Lauren
Varney
lauren.varney.21@ucl.ac.uk
Rosemary
Abidoph
rosemary.abidoph@nhs.net
Maria
Richards-Brown
mrichards.brown@gmail.com
Prof
Elvira
Bramon
e.bramon@ucl.ac.uk
Emmanuel
Rollings-Kamara
emmanuel.rollings-kamara@nihr.ac.uk
Prof
Elvira
Bramon
e.bramon@ucl.ac.uk
Oriella
Stellakis
uctvocs@ucl.ac.uk
Lauren
Varney
uctvlva@ucl.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by University College London and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 41824
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
